Clinical trials: Secondary Progressive Multiple Sclerosis
Multiple Sclerosis, Chronic Progressive
China Betaferon Adherence, Coping and Nurse Support Study
Non-adherence reduces treatment benefit and can bias the assessment of treatment efficacy thereby involving safety risks for the patient and influencing health cost-effectiveness.
- Trial name
- NCT01436838
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Bayer
Multiple Sclerosis
Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis
The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the visual improvement of patients suffering from chronic visual loss resulting from multiple sclerosis related optic neuritis.
- Trial name
- MS-ON (NCT02220244)
- Testing
- MD1003 100mg capsule
- Where
- 20 sites in France, United Kingdom
- Volunteers
- 105 people
- Sponsor
- MedDay Pharmaceuticals SA
Secondary Progressive Multiple Sclerosis
Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis
To determine whether simvastatin at a dose of 80mg can reduce the rate of whole brain atrophy, as measured by MRI, over a 2-year time-period when compared to placebo.
- Trial name
- MS-STAT (NCT00647348)
- Testing
- Simvastatin
- Where
- 3 sites in United Kingdom
- Volunteers
- 140 people
- Sponsor
- Imperial College London
Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis
The purpose of the study is to determine the safety and tolerability, dose-limiting toxicities, maximum tolerated dose, and recommended therapeutic dose of intravenously administered MIS416 weekly in patients with chronic…
- Trial name
- NCT01191996
- Testing
- MIS416
- Where
- New Zealand
- Volunteers
- 34 people
- Sponsor
- Innate Immunotherapeutics
Relapsing Remitting Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive
Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients
Scientific background: Growing awareness and accumulating data regarding the cognitive impairment and its progression in multiple sclerosis (MS) patients has received an important place in neurological research in the last decade.
- Trial name
- NCT00220493
- Testing
- Ritalin
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Sheba Medical Center
Secondary Progressive Multiple Sclerosis (SPMS)
Multiple Sclerosis-Simvastatin Trial 2
Multiple Sclerosis (MS) is a progressive neurological disorder of the brain and spinal cord. It affects approximately 120,000 people in the United Kingdom and 2.5 million people globally.
- Trial name
- MS-STAT2 (NCT03387670)
- Testing
- Simvastatin
- Where
- 31 sites in United Kingdom
- Volunteers
- 964 people
- Sponsor
- University College, London
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
The Synergistic Effects of AIH and FES in Persons With MS
The purpose of this study is to examine how neuromuscular electrical stimulation (NMES), may synergistically enhance corticospinal excitability in people with relapsing form multiple sclerosis (MS).
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT06413602
- Testing
- Acute Intermittent Hypoxia, Neuromuscular Electrical Stimulation
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shirley Ryan AbilityLab
Secondary Progressive Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive
Novel Imaging Markers in SPMS
This pilot study takes the innovative approach of using ultrasmall superparamagnetic iron oxide (USPIO) nanoparticle enhanced MRI to measure activity of the innate immune system within MS lesions.
- Conditions
- Secondary Progressive Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis
- Trial name
- NCT05357833
- Testing
- Ferumoxytol infusion, Gadoteridol, MRI Brain and Cervical Spine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Utah
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Cortical Lesions in Patients With Multiple Sclerosis
Multiple sclerosis (MS) is an autoimmune disease, leading to inflammation and degeneration of neurons in the entire central nervous system (CNS).
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
- Trial name
- CLiMS (NCT03653585)
- Where
- Denmark
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Danish Research Centre for Magnetic Resonance
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS
The primary objective is to establish the safety of administration of intranasal Foralumab in non-active primary and secondary progressive Multiple Sclerosis (MS) patients in a multiple ascending dose format in escalating doses…
- Conditions
- Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Multiple Sclerosis
- Trial name
- NCT05029609
- Testing
- Intranasal Foralumab Solution
- Sponsor
- Tiziana Life Sciences LTD
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive
An Observational Biomarker Study in Multiple Sclerosis (MS) Patients
All males and females between 18-70 years of age regardless of their race and ethnicity with a confirmed diagnosis of Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), and Relapse…
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT05663853
- Where
- 4 sites in United States
- Volunteers
- 137 people
- Sponsor
- LAPIX Therapeutics Inc.
Multiple Sclerosis, Relapsing-remitting, Multiple Sclerosis, Secondary Progressive
Bayer/Cognitive Assessments With Multiple Sclerosis Subjects
This study is designed to identify a brief screening evaluation for MS patients that is sensitive and specific to the MS population and which correlates with the findings of our standard-of-care neuropsychological assessments.
- Trial name
- NCT00888277
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of Louisville
Multiple Sclerosis
A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With Exacerbations
The study goal is to establish the equivalence of pharmacokinetic (PK) properties, as well as the comparability of safety, immunogenicity (IG) and pharmacodynamics (PD) of the drug product RPH-035 (R-Pharm JSC, Russia) in…
- Trial name
- NCT07597668
- Testing
- RPH-035, Ocrevus®
- Where
- 23 sites in Russia
- Volunteers
- 180 people
- Sponsor
- R-Pharm
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis
This was a multicenter, non-interventional, retrospective study aiming to evaluate the real-world effectiveness and safety of siponimod treatment in Chinese patients with relapsing forms of multiple sclerosis (RMS).
- Conditions
- Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Trial name
- NCT06395909
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- Novartis
Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS)
Evaluation of an Online, On Demand Multimodal Wellness Program to Reduce Fatigue and Improve Quality of Life in Progressive Multiple Sclerosis.
The goal of this clinical trial is to learn if an online wellness program can lower fatigue and improve mood and quality of life in people with progressive multiple sclerosis who are 45 to 70 years old and are experiencing…
- Trial name
- DEW (NCT07831928)
- Testing
- Online wellness course and online exercise platform, Usual Care Group
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- University of Iowa
Multiple Sclerosis
Wahls Paleo Diet and Progressive Multiple Sclerosis
Based on favorable preliminary data from ongoing studies testing the safety and tolerability of a nutrition, exercise and neuromuscular electrical stimulation funded by Direct MS, the investigators are proposing a pilot study…
- Trial name
- NCT01915433
- Testing
- Wahls Paleo Plus, Wahls Diet
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Terry L. Wahls
Secondary Progressive Multiple Sclerosis
AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis
Patients with marked bladder dysfunction as a result of secondary progressive multiple sclerosis are being recruited to receive AIMSPRO or placebo by subcutaneous injection, in this double-blind crossover study.
- Trial name
- NCT01228396
- Testing
- Hyperimmune caprine serum against HIV lysate
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Daval International Limited
Secondary Progressive Multiple Sclerosis
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
Foralumab is a human anti-CD3 monoclonal antibody being developed for the treatment of autoimmune and inflammatory diseases. The goal of this Phase 2a, randomized, double-blind placebo-controlled, multicenter dose-ranging study…
- Trial name
- NCT06292923
- Testing
- Foralumab
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- Tiziana Life Sciences LTD
Secondary Progressive Multiple Sclerosis
Study Evaluating Mitoxantrone in Multiple Sclerosis
The purpose of this study is to show the dose-response relationship of three doses of mitoxantrone with regard to efficacy in patients with secondary progressive multiple sclerosis and to show the safety and tolerability of…
- Trial name
- NCT00146159
- Testing
- Mitoxantrone
- Where
- 7 sites in Germany
- Volunteers
- 336 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis
This study will evaluate if giving insulin that is administered in the nostrils (intranasal) is safe and tolerable for people with multiple sclerosis (MS).
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
- Trial name
- NCT02988401
- Testing
- Insulin
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Johns Hopkins University